Charles River Laboratories (CRL) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $288.50 --0%
EPS Growth %: +21.8%
Financial Fact:
Interest income: 523K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Interest income: 523K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.12, $0.62 better than the analyst estimate of $2.50. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $984.86 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $9.90-$10.10, versus the consensus of $9.65.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- NXP Semiconductors NV (NXPI) Reiterated at Overweight by Cantor Fitzgerald
- Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
